Cargando…
STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models
Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with hitherto unseen responses at advanced and metastatic stages of the disease. However, the aggressive brain tumor glioblastoma (GBM) is highly immunosuppressive and remains largely refractory to current immunotherap...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282249/ https://www.ncbi.nlm.nih.gov/pubmed/35787058 http://dx.doi.org/10.1073/pnas.2111003119 |
_version_ | 1784747065860947968 |
---|---|
author | Berger, Gilles Knelson, Erik H. Jimenez-Macias, Jorge L. Nowicki, Michal O. Han, Saemi Panagioti, Eleni Lizotte, Patrick H. Adu-Berchie, Kwasi Stafford, Alexander Dimitrakakis, Nikolaos Zhou, Lanlan Chiocca, E. Antonio Mooney, David J. Barbie, David A. Lawler, Sean E. |
author_facet | Berger, Gilles Knelson, Erik H. Jimenez-Macias, Jorge L. Nowicki, Michal O. Han, Saemi Panagioti, Eleni Lizotte, Patrick H. Adu-Berchie, Kwasi Stafford, Alexander Dimitrakakis, Nikolaos Zhou, Lanlan Chiocca, E. Antonio Mooney, David J. Barbie, David A. Lawler, Sean E. |
author_sort | Berger, Gilles |
collection | PubMed |
description | Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with hitherto unseen responses at advanced and metastatic stages of the disease. However, the aggressive brain tumor glioblastoma (GBM) is highly immunosuppressive and remains largely refractory to current immunotherapeutic approaches. The stimulator of interferon genes (STING) DNA sensing pathway has emerged as a next-generation immunotherapy target with potent local immune stimulatory properties. Here, we investigated the status of the STING pathway in GBM and the modulation of the brain tumor microenvironment (TME) with the STING agonist ADU-S100. Our data reveal the presence of STING in human GBM specimens, where it stains strongly in the tumor vasculature. We show that human GBM explants can respond to STING agonist treatment by secretion of inflammatory cytokines. In murine GBM models, we show a profound shift in the tumor immune landscape after STING agonist treatment, with massive infiltration of the tumor-bearing hemisphere with innate immune cells including inflammatory macrophages, neutrophils, and natural killer (NK) populations. Treatment of established murine intracranial GL261 and CT-2A tumors by biodegradable ADU-S100–loaded intracranial implants demonstrated a significant increase in survival in both models and long-term survival with immune memory in GL261. Responses to treatment were abolished by NK cell depletion. This study reveals therapeutic potential and deep remodeling of the TME by STING activation in GBM and warrants further examination of STING agonists alone or in combination with other immunotherapies such as cancer vaccines, chimeric antigen receptor T cells, NK therapies, and immune checkpoint blockade. |
format | Online Article Text |
id | pubmed-9282249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | National Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-92822492023-01-05 STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models Berger, Gilles Knelson, Erik H. Jimenez-Macias, Jorge L. Nowicki, Michal O. Han, Saemi Panagioti, Eleni Lizotte, Patrick H. Adu-Berchie, Kwasi Stafford, Alexander Dimitrakakis, Nikolaos Zhou, Lanlan Chiocca, E. Antonio Mooney, David J. Barbie, David A. Lawler, Sean E. Proc Natl Acad Sci U S A Biological Sciences Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with hitherto unseen responses at advanced and metastatic stages of the disease. However, the aggressive brain tumor glioblastoma (GBM) is highly immunosuppressive and remains largely refractory to current immunotherapeutic approaches. The stimulator of interferon genes (STING) DNA sensing pathway has emerged as a next-generation immunotherapy target with potent local immune stimulatory properties. Here, we investigated the status of the STING pathway in GBM and the modulation of the brain tumor microenvironment (TME) with the STING agonist ADU-S100. Our data reveal the presence of STING in human GBM specimens, where it stains strongly in the tumor vasculature. We show that human GBM explants can respond to STING agonist treatment by secretion of inflammatory cytokines. In murine GBM models, we show a profound shift in the tumor immune landscape after STING agonist treatment, with massive infiltration of the tumor-bearing hemisphere with innate immune cells including inflammatory macrophages, neutrophils, and natural killer (NK) populations. Treatment of established murine intracranial GL261 and CT-2A tumors by biodegradable ADU-S100–loaded intracranial implants demonstrated a significant increase in survival in both models and long-term survival with immune memory in GL261. Responses to treatment were abolished by NK cell depletion. This study reveals therapeutic potential and deep remodeling of the TME by STING activation in GBM and warrants further examination of STING agonists alone or in combination with other immunotherapies such as cancer vaccines, chimeric antigen receptor T cells, NK therapies, and immune checkpoint blockade. National Academy of Sciences 2022-07-05 2022-07-12 /pmc/articles/PMC9282249/ /pubmed/35787058 http://dx.doi.org/10.1073/pnas.2111003119 Text en Copyright © 2022 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Biological Sciences Berger, Gilles Knelson, Erik H. Jimenez-Macias, Jorge L. Nowicki, Michal O. Han, Saemi Panagioti, Eleni Lizotte, Patrick H. Adu-Berchie, Kwasi Stafford, Alexander Dimitrakakis, Nikolaos Zhou, Lanlan Chiocca, E. Antonio Mooney, David J. Barbie, David A. Lawler, Sean E. STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models |
title | STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models |
title_full | STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models |
title_fullStr | STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models |
title_full_unstemmed | STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models |
title_short | STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models |
title_sort | sting activation promotes robust immune response and nk cell–mediated tumor regression in glioblastoma models |
topic | Biological Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282249/ https://www.ncbi.nlm.nih.gov/pubmed/35787058 http://dx.doi.org/10.1073/pnas.2111003119 |
work_keys_str_mv | AT bergergilles stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT knelsonerikh stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT jimenezmaciasjorgel stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT nowickimichalo stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT hansaemi stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT panagiotieleni stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT lizottepatrickh stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT aduberchiekwasi stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT staffordalexander stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT dimitrakakisnikolaos stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT zhoulanlan stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT chioccaeantonio stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT mooneydavidj stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT barbiedavida stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels AT lawlerseane stingactivationpromotesrobustimmuneresponseandnkcellmediatedtumorregressioninglioblastomamodels |